Secondary efficacy end factors included a sustained virologic response at four weeks after treatment and at 24 weeks after treatment. Safety end factors included adverse events, discontinuation of a report drug because of adverse events, and grade 3 or 4 4 laboratory abnormalities. Statistical Analysis With sample sizes of 14, 20, and 40 patients, the likelihood of observing at least one safety event occurring at an incidence price of 10 percent was 0.771, 0.878, and 0.985, respectively. With these three sample sizes, the two-sided 80 percent exact self-confidence intervals for a sustained virologic response at week 12 after treatment had been, respectively, 58 to 92 percent if the observed price was 79 percent , 59 to 87 percent if the observed rate was 75 percent , and 64 to 84 percent if the observed price was 75 percent .U.S. Product sales elevated 3.4 % to $758 million, driven by solid sales of pharmaceutical products primarily, which grew 9.1 %. Product sales of allergy pharmaceutical items rose 19.0 % as a result of a strong fall allergy time of year. Surgical development was negatively affected by a solid comparable quarter in 2009 2009. Heavy promotional activity in the third quarter had a residual adverse impact on sales of lens disinfectants in the 4th quarter. Sales in international markets rose 7.7 % on an organic basis to $1.05 billion with balanced contributions from most global markets. Sales in emerging marketplaces increased 13.1 % organically , led by the BRIC nations , which rose 17.2 % on an organic basis .